Mouse Anti-Feline CD8-UNLB抗體 | 貨號8120-01

代理廠牌：
原廠連結：	https://www.southernbiotech.com
相關下載：	Mouse Anti-Feline CD8-UNLB抗體操作手冊

特點

Mouse Anti-Feline CD8-UNLB抗體 | 貨號8120-01 規格1.0 mL

美國抗體生產商Southern Biotech於1982年，由UAB細胞免疫專家Dr. Max Cooper與實驗室成員共同創立。SouthernBiotech致力於生產高品質二級抗體，目前除了一般常見的多株與單株二級抗體外，還帶有螢光物質（FITC、Spectral Red、Alexa 488、Alexa 647、Pacific Blue）、酵素（HRP、AP）、Low Endotoxin/Azide Free（LE/AF）等標定，以及F(ab)和F(ab’)2等抗體片段。諸如此類多樣化產品，協助各種實驗進行。

二級抗體 (Secondary antibodies) 應用:

二抗(Secondary antibodies)是針對免疫球蛋白（immunoglobulin , Ig）分子的多克隆(polyclonal) 和單克隆抗體(monoclonal antibodies)。它們通常與抗原特異性一抗(specific primary antibody) 一起使用，並且通常被標定酵素或螢光物質以幫助檢測。二抗可用於多種應用，例如ELISA、免疫印跡(Immunoblotting)、流式細胞儀(Flow Cytometry)、免疫組織染色(Immunohistochemistry)、免疫細胞化學(Immuocytochemistry)。二級抗體通常用酶或螢光染料標記，這使得能夠通過比色，化學發光和螢光技術進行檢測。例如，酶辣根過氧化物酶（enzymes horseradish peroxidase , HRP）和鹼性磷酸酶（alkaline phosphatase , AP）通過比色和化學發光平台在ELISA和蛋白質印跡應用中是有價值的。螢光蛋白諸如螢光素（fluorescein , FITC），藻紅蛋白（phycoerythrin , PE）和花青（cyanine , CY）的螢光染料在螢光的應用中是必不可少的，包括流式細胞術，免疫螢光顯微術和多重測定。二抗允許標記和檢測的靈活性以及通過信號放大，可增加的靈敏度。

產品介紹: Mouse Anti-Feline CD8-UNLB，不具標誌。針對Feline/Lion/Tsushima Leopard Cat CD8β具特異性。緩衝液配方在Borate buffered saline, pH 8.2。

Feline peripheral blood lymphocytes were stained with Mouse Anti-Feline CD8-PE (SB Cat. No. 8120-09) and Mouse Anti-Feline CD4-FITC (SB Cat. No. 8130-02).

Clone	fCD8
Isotype	Mouse (CAF1) IgG₁κ
Isotype Control	Mouse IgG₁-UNLB
Immunogen	Feline thymocytes
Specificity	Feline/Lion/Tsushima Leopard Cat CD8β
Alternalte Name(s)	fCD8
Description	Feline CD8, a member of the immunoglobulin superfamily of cell surface receptors, is a type II transmembrane glycoprotein that is expressed as a heterodimer on the suppressor/cytotoxic subpopulation of peripheral T lymphocytes. It is present on approximately 76% of thymocytes, 14% of splenocytes, 1% of bone marrow cells, and 15% of peripheral blood lymphocytes. CD8 functions as a co-receptor with MHC Class I-restricted T cell receptors in antigen recognition.
Format/Conjugate	UNLB (Unconjugated)
Buffer Formulation	Borate buffered saline, pH 8.2
Concentration	0.5 mg/mL
Volume	1.0 mL
Storage & Handling	2-8°C Please refer to product specific SDS
Applications	Applications for relevant formats of this clone include – Flow Cytometry – Quality tested ^1,5-23 Immunohistochemistry-Frozen Sections – Reported in literature ^2,3 Immunocytochemistry – Reported in literature ¹ Immunoprecipitation – Reported in literature ¹ Separation – Reported in literature ⁴
Recommended Dilutions	Please refer to product specific Technical Bulletin
RRID	AB_2796409

Gene ID	493948 (Feline)
Gene Symbol	CD8B (Feline)
Uniprot ID	P79336 (Feline)
Uniprot Name	CD8B_FELCA
Gene ID	493775 (Feline)
Gene Symbol	CD4 (Feline)
Uniprot ID	P79355 (Feline)
Uniprot Name	P79355_FELCA
Gene ID	16019 (Mouse)
Gene Symbol	Ighm (Mouse)
Gene Aliases	AI326478; Igh-6; Igh-M; Igh6; Igm; muH
Uniprot ID	P01872 (Mouse)
Uniprot Name	IGHM_MOUSE

References

Klotz FW, Cooper MD. A feline thymocyte antigen defined by a monoclonal antibody (FT2) identifies a subpopulation of non-helper cells capable of specific cytotoxicity. J Immunol. 1986;136:2510-4. (Immunogen, FC, ICC, IP)
Rideout BA, Lowenstine LJ, Hutson CA, Moore PF, Pedersen NC. Characterization of morphologic changes and lymphocyte subset distribution in lymph nodes from cats with naturally acquired feline immunodeficiency virus infection. Vet Pathol. 1992;29:391-9. (IHC-FS)
Femenia F, Crespeau F, Fontaine JJ, Boucheix C, Parodi AL. Early haematological and pathological abnormalities of pathogen-free cats experimentally infected with feline immunodeficiency virus (FIV). Vet Res. 1994;25:544-54. (IHC-FS, FC)
Choi I, Hokanson R, Collisson EW. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8+ T lymphocytes suppresses FIV replication. J Virol. 2000;74:676-83. (Sep)
Nishimura Y, Goto Y, Yoneda K, Endo Y, Mizuno T, Hamachi M, et al. Interspecies transmission of feline immunodeficiency virus from the domestic cat to the Tsushima cat (Felis bengalensis euptilura) in the wild. J Virol. 1999;73:7916-21. (FC, Tsushima Reactivity)
Hohdatsu T, Hirabayashi H, Motokawa K, Koyama H. Comparative study of the cell tropism of feline immunodeficiency virus isolates of subtypes A, B and D classified on the basis of the env gene V3-V5 sequence. J Gen Virol. 1996;77:93-100. (FC)
Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol. 1996;70:5165-9. (FC)
Shimojima M, Miyazawa T, Kohmoto M, Ikeda Y, Nishimura Y, Maeda K, et al. Expansion of CD8α+β- cells in cats infected with feline immunodeficiency virus. J Gen Virol. 1998;79:91-4. (FC)
Barr MC, Billaud J, Selway DR, Huitron-Resendiz S, Osborn KG, Henriksen SJ, et al. Effects of multiple acute morphine exposures on feline immunodeficiency virus disease progression. J Infect Dis. 2000;182:725-32. (FC)
Phipps AJ, Hayes KA, Buck WR, Podell M, Mathes LE. Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. J Acquir Immune Defic Syndr. 2000;23:8-16. (FC)
Hokanson RM, TerWee J, Choi I, Coates J, Dean H, Reddy DN, et al. Dose response studies of acute feline immunodeficiency virus PPR strain infection in cats. Vet Microbiol. 2000;76:311-27. (FC)
Barr MC, Huitron-Resendiz S, Selway DR, Henriksen SJ, Phillips TR. Exogenous glucocorticoids alter parameters of early feline immunodeficiency virus infection. J Infect Dis. 2000;181:576-86. (FC)
Hohdatsu T, Yamazaki A, Yamada M, Kusuhara H, Kaneshima T, K oyama H. Ability of CD8+ T cell anti-feline immunodeficiency virus activity correlated with peripheral CD4+ T cell counts and plasma viremia. Microbiol Immunol. 2003;47:765-73. (FC)
de Groot-Mijnes JD, van Dun JM, van der Most RG, de Groot R. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J Virol. 2005;79:1036-44. (FC)
Broche-Pierre S, Richardson J, Moraillon A, Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. J Gen Virol. 2005;86:2495-506. (FC)
El Garch H, Richard S, Piras F, Leard T, Poulet H, Andreoni C, et al. Feline leukemia virus (FeLV)-specific IFNγ+ T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. Int J Appl Res Vet Med. 2006;4:100-8. (FC)
Brennan G, Podell MD, Wack R, Kraft S, Troyer JL, Bielefeldt-Ohmann H, et al. Neurologic disease in captive lions (Panthera leo) with low-titer lion lentivirus infection. J Clin Microbiol. 2006;44:4345-52. (FC, Lion Reactivity)
Dean GA, LaVoy A, Yearley J, Stanton C. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats. J Infect Dis. 2006;193:1520-7. (FC)
Pepin AC, Tandon R, Cattori V, Niederer E, Riond B, Willi B, et al. Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats. Virus Res. 2007;127:9-16. (FC)
Maksaereekul S, Dubie RA, Shen X, Kieu H, Dean GA, Sparger EE. Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-α plasmids preserves global CD4 T lymphocyte function after challenge with FIV. Vaccine. 2009;27:3754-65. (FC)
Thompson J, MacMillan M, Boegler K, Wood C, Elder JH, VandeWoude S. Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3′ elements. PLoS One. 2011;6(8):e24020. (FC)
Novacco M, Boretti FS, Franchini M, Riond B, Meli ML, Hofmann-Lehmann R. Protection from reinfection in “Candidatus Mycoplasma turicensis”-infected cats and characterization of the immune response. Vet Res. 2012;43:82. (FC)
Hicks CA, Willi B, Riond B, Novacco M, Meli ML, Stokes CR, et al. Protective Immunity against Infection with Mycoplasma haemofelis. Clin Vaccine Immunol. 2015;22:108-18. (FC)

↑回到頁首↑